- Home
- HOOK vs INAB Comparison
HOOK vs INAB Comparison
Compare HOOK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- INAB
- Stock Information
- Founded
- HOOK 2011
- INAB 2016
- Country
- HOOK United States
- INAB United States
- Employees
- HOOK N/A
- INAB N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- INAB Health Care
- Exchange
- HOOK Nasdaq
- INAB Nasdaq
- Market Cap
- HOOK 15.3M
- INAB 14.5M
- IPO Year
- HOOK 2019
- INAB 2021
- Fundamental
- Price
- HOOK $1.20
- INAB $2.50
- Analyst Decision
- HOOK Buy
- INAB Strong Buy
- Analyst Count
- HOOK 4
- INAB 2
- Target Price
- HOOK $10.67
- INAB $108.00
- AVG Volume (30 Days)
- HOOK 65.1K
- INAB 244.7K
- Earning Date
- HOOK 08-07-2025
- INAB 08-07-2025
- Dividend Yield
- HOOK N/A
- INAB N/A
- EPS Growth
- HOOK N/A
- INAB N/A
- EPS
- HOOK N/A
- INAB N/A
- Revenue
- HOOK $9,351,000.00
- INAB N/A
- Revenue This Year
- HOOK N/A
- INAB N/A
- Revenue Next Year
- HOOK N/A
- INAB N/A
- P/E Ratio
- HOOK N/A
- INAB N/A
- Revenue Growth
- HOOK N/A
- INAB N/A
- 52 Week Low
- HOOK $0.72
- INAB $2.05
- 52 Week High
- HOOK $6.77
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- INAB 38.92
- Support Level
- HOOK $1.13
- INAB $2.10
- Resistance Level
- HOOK $1.35
- INAB $2.30
- Average True Range (ATR)
- HOOK 0.06
- INAB 0.12
- MACD
- HOOK -0.01
- INAB 0.09
- Stochastic Oscillator
- HOOK 40.64
- INAB 95.06
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.